{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-056949","form_type":"8-K","ticker":null,"cik":"0001888012","company_name":"HilleVax, Inc.","filed_at":"2024-05-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:21.097647+00:00","generated_at":"2026-06-02T07:12:31.712591+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"HilleVax Q1 net loss widens to $46.8M; cash at $272.7M; NEST-IN1 data due mid-2024","bullets":["Net loss $46.8M vs $26.9M YoY; R&D expenses $26.0M (up from $23.2M); G&A $8.5M (up from $5.8M).","Cash, equivalents and marketable securities $272.7M as of March 31, 2024, down from $303.5M at Dec 31, 2023.","Topline safety and efficacy data from NEST-IN1 Phase 2b trial of HIL-214 in infants expected in mid-2024.","Appointed Sean McLoughlin as COO during Q1 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-056949","json":"https://secwatch.observer/filing/0000950170-24-056949.json","markdown":"https://secwatch.observer/filing/0000950170-24-056949.md","text":"https://secwatch.observer/filing/0000950170-24-056949.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1888012/000095017024056949/0000950170-24-056949-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1888012/000095017024056949/hlvx-20240509.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T07:12:31.712591+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"b4ec08ee4dc162b4535c76576390911790e0c1ba","claim":"HilleVax, Inc. reported the quarter ended March 31, 2024 results: net income Net loss for the first quarter 2024 was $46.8 million, compared to $26.9 million for the first quarter 2023.","evidence_excerpt":"HilleVax, Inc. (the \"Company\") issued a press release announcing its financial results for the quarter ended March 31, 2024.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1888012/000095017024056949/0000950170-24-056949-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended March 31, 2024"},{"label":"Net income","value":"Net loss for the first quarter 2024 was $46.8 million, compared to $26.9 million for the first quarter 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}